MONTREAL, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Defence Therapeutics (OTCQB: DTCFF), based in adMare BioInnovations Technoparc, Montreal, focused on advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, today announced that Amie Phinney, PhD, MBA, Strategy & Business – Director, will present live at Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on December 11th.
DATE: December 11th
TIME: 11:00am ET
LINK: REGISTER HERE
Available for 1x1 meetings: December 11, between 2:00-5:00pm ET, December 15 between 10:00-3:00pm ET and December 16 between 10:00-5:00pm ET. Schedule 1x1 Meetings here
This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more about the event at www.virtualinvestorconferences.com.
Recent Company Highlights
- in Vivo efficacy results validation evaluating Accum-Kadcyla in breast cancer models
- Expanding the lab capacity and assays
- Formation of a strong Scientific Advisory Board
About Defence Therapeutics
Defence Therapeutics is a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of biologics in their intact form to target cells. As a result, efficacy and potency can be enhanced for biologics enabling expanded patient access and market opportunities.
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
CONTACTS:
Defence Therapeutics Inc.
Sébastien Plouffe
Chief Executive Officer
(514) 947-2272
splouffe@defencetherapeutics.com
Virtual Investor Conferences
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com
